immune modulator News
-
20th Annual Biotech in Europe Forum for global partnering & investments
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners. Please contact us for a personal meeting within the partnering system or outside it. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in ...
-
Bio International Convention Digital June 8-12, 2020
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) . We look forward meeting potential investors and licensing partners. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome ...
-
New company name and website
We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV). “During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original ...
-
Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate
First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven ...
By Exscientia
-
Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced the results from two clinical studies using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual MDS patients were featured in two poster presentations at the 63rd American Society of ...
-
Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications
Creative BioMart, a renowned provider of innovative life science research solutions, proudly announces its extensive selection of lectins catering to a broad range of research endeavors. Lectins, a class of carbohydrate-binding proteins, hold immense significance in the scientific realm due to their diverse biological functions, encompassing cell adhesion, signal transduction, and immune ...
-
Creative Enzymes Unveils a Diverse Range of Premium Extracts for Various Applications
Creative Enzymes, a prominent player in the biotechnology sector, proudly introduces an innovative line-up of exceptional extracts, tailored to meet a wide spectrum of application needs. From plant extracts and animal extracts to mushroom extracts and vegetable powders, etc., this new collection promises to redefine the utilization of natural ingredients across industries. In a dynamic world ...
-
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company’s CXCR3 chemokine receptor modulator, SG-3-06686 (referred to as SG-3-00802DC in the AACR ...
-
Genmab and Synaffix Enter into $415m License Agreement for ADC Technology
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single ...
By Synaffix BV
-
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation ...
-
ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully. Moreover, in a follow-up ...
-
Creative Enzymes Revolutionizes the Probiotics Industry with Bacillus Coagulans Freeze Dried Powder
Creative Enzymes, a professional enzyme provider located in New York, USA, proudly unveils its high-quality product, Bacillus Coagulans Freeze Dried Powder. This cutting-edge probiotic powder not only offers a multitude of health benefits but also ushers in unprecedented opportunities for the food and pharmaceutical industries. Bacillus Coagulans, a resilient and spore-forming bacterium, has ...
-
ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), had successfully completed two Phase I/IIa clinical trials in glioblastoma and pancreatic cancer, respectively. The new data show that ...
-
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientific ...
-
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM ...
-
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert ...
-
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million. The funding will be used to develop a rapid diagnostic that will identify immune subtypes ...
-
Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits
Creative Enzymes, a leading provider of innovative enzymes and probiotic solutions, is proud to introduce a range of Lactobacillus strains with enhanced benefits that are designed to revolutionize the way we approach gut health. This high-quality probiotic powder not only offers a wide range of health benefits but also opens up new opportunities for the food and pharmaceutical industries. In ...
-
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer ...
-
Announcing the Release of MiXCR 4.0, a Powerful Tool for Immunome Profiling
MiLaboratories, the global leader in immunome profiling software development, today announced the release of a new version of its flagship product, MiXCR 4.0. MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you